MSF and global TB activists take stage at annual TB conference
November 13, 2024Activists present ‘Time for $5’ petition signed by over 206,000 people asking US corporations Cepheid and Danaher to drop test prices Bali/Geneva, 12 November 2024 – At the annual TB Union Conference, taking place in Bali, Indonesia, over 70 TB activists, including...
Read more‘Time for $5’ campaign to deliver 206,937 signatures to US corporation Danaher in Washington, DC, demanding a $5 price for their medical tests
October 17, 2024US test maker Cepheid and parent corporation Danaher have ignored global calls for price reductions and have broken their promise from one year ago to be transparent about what it costs to make their medical tests Washington, DC, 17 October...
Read moreUnited States: MSF resumes support to local groups helping migrants in Arizona desert
August 22, 2024Doctors Without Borders/Médecins Sans Frontières(MSF) is resuming its work in support of Tucson-based nonprofit groups that are bringing humanitarian aid to migrants and asylum seekers crossing the US-Mexico border near the Sonoran Desert, the organization announced today. Earlier this year, a...
Read moreMSF welcomes Indian Patent Office’s rejection of J&J’s application for paediatric formulation of lifesaving TB drug
July 17, 2024Mumbai, 17 July 2024 – On Friday 5 July 2024, the “pre-grant opposition” filed in December 2020 by The Delhi Network of Positive People (DNP+) and a Mumbai-based tuberculosis (TB) survivor Ganesh Acharya, and supported by Médecins Sans Frontières/Doctors Without...
Read moreDanaher continues to charge exorbitant prices for lifesaving medical tests despite urgent demands for price reductions by several Ministries of Health
June 18, 2024Geneva, 17 June 2024 - In September 2023, the US corporation Danaher, which owns diagnostics maker Cepheid, announced a price reduction of the primary GeneXpert test used to diagnose tuberculosis (TB), from US$9.98 to $7.97, amid pressure from TB activists....
Read moreUrgent call for Europe to improve treatment access for tuberculosis: Many TB medicines and formulations accessible in lower- and middle-income countries remain unaffordable or unavailable in Europe
June 7, 2024Berlin, 6 June 2024: As the World Health Organization (WHO) concluded a meeting with European health officials and civil society to improve access to tuberculosis (TB) medicines in the European Union (EU)/European Economic Area (EEA), Médecins Sans Frontières/Doctors Without Borders...
Read moreGavi’s next strategy must make sure to reach the 10 million children in fragile and humanitarian settings who are missing vaccines
June 4, 2024Where are we now? This week, on 6-7 June 2024, the Board of Gavi, the Vaccine Alliance, is meeting in Geneva to approve and endorse the one-page framework for Gavi 6.0, which outlines its strategy for the five-year period from...
Read moreMSF welcomes Indian government standing strong against EFTA trade deal’s harmful intellectual property provisions
February 15, 2024Geneva/New Delhi, 15 February 2024 — In a welcome move today, the Indian Commerce Ministry confirmed its rejection of Switzerland's demand for data exclusivity for medicines in the India-EFTA trade deal, and emphasised the importance of protecting the country’s generic...
Read moreMillions of peoples’ access to affordable medicines at risk if India-EFTA trade deal finalised as is
February 14, 2024Text leaked yesterday shows India-EFTA trade deal includes excessive intellectual property provisions that may require India to gut pro-public health national laws.Geneva/New Delhi, 14 February 2024 — Following news that India and the European Free Trade Association (EFTA) – which...
Read moreMSF warns governments are failing to test, treat and prevent TB in children
November 14, 2023Governments must immediately implement the latest WHO guidelines to stop children from dying from this deadly yet curable disease Geneva, 14 November 2023 - Médecins Sans Frontières/Doctors Without Borders (MSF) welcomed the World Health Organization’s (WHO) ‘Roadmap towards ending TB in...
Read moreMSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries
September 30, 202330 September 2023, Geneva Christophe Perrin, TB Advocacy Pharmacist, MSF Access Campaign: “We welcome Johnson & Johnson’s (J&J) announcement finally paving the way for unfettered access to affordable generic versions of bedaquiline for all people living with drug-resistant tuberculosis (DR-TB) who need...
Read moreTransforming lives in Mozambique: surgical treatment for patients with neglected diseases in Mogovolas district
July 25, 2023Nampula, July 21 , 2023 – Médecins Sans Frontières/Doctors Without Borders (MSF) is collaborating with the District Services of Health, Women and Social Action in Mogovolas and the Provincial Services in Nampula, Mozambique, to deliver surgical treatment for hydrocele, one...
Read more